Personalis, Inc. (PSNL)
Nasdaq · Healthcare · Diagnostics & Research
$16.40+0.74%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $1.8B
- 52-week range
- $4.96 – $18.89
- 52-week change
- +126.11%
- EPS (trailing)
- −$1.09
- Next earnings
- Nov 3, 2026
Fiscal year to Dec 2025
- Revenue
- $69.6M (−17.69%)
- Net income
- −$81.3M
- Operating margin
- −126.4%
- Diluted EPS
- −$0.91
- Free cash flow
- −$79.5M
From the company’s annual report on SEC EDGAR.
About Personalis, Inc.
Personalis, Inc. develops, markets, and sells advanced cancer genomic tests and services in the United States and internationally. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD), therapy response and recurrence monitoring in solid tumor cancers; and ImmunoID NeXT, a tissue-based service that combines whole exome and whole transcriptome sequencing data with advanced analytics to provide a multi-dimensional view of the tumor and the tumor microenvironment from a single sample. It also provides NeXT Personal Dx, a tumor-informed liquid biopsy test for the detection of MRD; and NeXT Dx, a tumor profiling test that is used to help select therapy for a cancer patient and identify potential clinical trials for a patient. In addition, the company performs whole exome sequencing of cancer tissue and matched blood samples for diagnostic companies as an input to their products; and whole genome sequencing on human samples for research projects, such as population sequencing initiatives.
Headquarters: Fremont, United States · 259 employees · personalis.com